We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cellceutix Announces Kevetrin™ in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
Product News

Cellceutix Announces Kevetrin™ in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study

Cellceutix Announces Kevetrin™ in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study
Product News

Cellceutix Announces Kevetrin™ in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Cellceutix Announces Kevetrin™ in Combination with Radiation Delayed Tumor Growth by Twofold in Head and Neck Cancer Study"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cellceutix Corporation has provided additional research data on Kevetrin™, its p53 breakthrough anti-cancer compound.

Kevetrin™ was studied as combination therapy with radiation to treat human head and neck cancer lines implanted in animals. While tumors treated with Kevetrin™ or radiation alone each showed significant anti-tumor activity, tumors treated with Kevetrin™ followed by radiation one week later demonstrated superior results in controlling tumor size.

Since the sequence of Kevetrin™ followed by radiation outpaced the reverse (radiation then Kevetrin™), Kevetrin™ may be acting as a "radiosensitizer," a term used to describe sensitization of tumor cells to radiation at the cellular level. Further information on the study is available at http://www.cellceutix.com/product-candidates/kevetrin-our-lead-compound.html.

Dr. Krishna Menon, Chief Scientific Officer of Cellceutix, commented, "Our research to date has shown the potential of Kevetrin™ as a stand-alone therapy. This additional data demonstrates its value as a combination therapy.

We believe the radiosensitizer capacity of Kevetrin™ is once again attributable to its interaction with p53. The data that we have collected in our pre-clinical studies on Kevetrin™ gives me great hope that Cellceutix is developing a drug that one day will have a major impact on cancer treatments."

To provide investors with a greater understanding of Cellceutix, an audio interview has been conducted with The Green Baron Report. The webcast is available for listening or download at http://thegreenbaron.com/Webcasts.htm.

Advertisement